GHK CU Research Cycle Reference
Cycle structures observed in published research. For laboratory reference only — not a cycle recommendation.
⚠ FOR RESEARCH REFERENCE ONLY — NOT A CYCLE RECOMMENDATION. No clinically validated cycle protocols exist for GHK CU. All information derives from preclinical studies and is provided for educational purposes only. See our full disclaimer.
Cycle Structure Overview
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) research protocols typically examine short-term application periods given its rapid plasma clearance within hours. Research suggests potential benefits for wound healing and skin remodeling, though clinical evidence remains limited (PMID: 22512572). This reference is for research methodology only and should not be interpreted as treatment recommendations.
Cycle Duration Research
Research protocols commonly examine 4-12 week application periods for topical formulations, though optimal duration remains unclear due to limited clinical data. The compound's short half-life may necessitate frequent dosing within research frameworks.
Dosing Progression
Topical research typically utilizes 0.1-1% concentrations in various formulations (PMID: 22512572). Research methodology often begins with lower concentrations (0.1-0.2%) to assess tolerance before potentially progressing to higher concentrations. Subcutaneous research protocols vary widely and lack standardization. Dosing frequency in research settings may range from daily to twice-daily application due to rapid clearance.
Post-Cycle Considerations
Research protocols examining GHK-Cu often include washout periods of 2-4 weeks between treatment phases to assess baseline return, though optimal washout duration remains undefined. The compound's short half-life suggests rapid clearance, but tissue effects may persist longer.
Stacking & Combination Cycles
Research has examined GHK-Cu in combination formulations, though systematic stacking research is limited. Some studies investigate 'glow-blend' type combinations with other peptides or growth factors, but interaction data remains preliminary and requires further investigation.
Frequently Asked Questions
-
Research indicates GHK-Cu may be relatively unstable in solution and sensitive to pH changes, potentially affecting bioavailability in research applications (PMID: 22512572).
-
The rapid plasma clearance within hours may require frequent dosing in research settings, though tissue penetration and local effects may persist longer than plasma levels suggest.
-
Topical research has primarily examined 0.1-1% concentrations, with most cosmetic research using the lower end of this range (PMID: 22512572).
-
Subcutaneous research protocols are less standardized than topical applications, with limited published methodology for this route of administration.